ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
GSK’s PD-1 inhibitor Jemperli approved in the UK pharmatimes
June 08, 2021GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. -
FDA approves GSK’s Jemperli for endometrial cancer pharmaceutical-technology
April 26, 2021The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) programmed death receptor-1 (PD-1) blocking antibody Jemperli (dostarlimab-gxly) based on its Biologics License Application (BLA) for endometrial cancer. -
Evrysdi leads latest CHMP recommendations pharmatimes
March 02, 2021The European Medicines Agency’s (EMA) Committee for Medicines for Human Use (CHMP) has recommended six medicines for approval at its February meeting.
Pharma Sources Insight January 2025
